Please provide your email address to receive an email when new articles are posted on . The most frequent cause of death in patients with rheumatoid arthritis-associated interstitial lung disease and ...
AIM-30 scoring system predicts 30-day mortality risk in IPF patients post-acute exacerbation using eight clinical variables. The system categorizes patients into low, moderate, and high-risk groups, ...
Pooled data from three key studies confirms that OFEV® slows disease progression by approximately 50% as measured by decline in forced vital capacity (FVC)*1-8 The pooled analysis also demonstrated ...
Patients with fibrotic interstitial lung disease hospitalized for acute respiratory worsening have a significant rate of morbidity regardless of an idiopathic pulmonary fibrosis diagnosis, according ...
Acute viral infection does not appear to be a primary cause of acute exacerbation of idiopathic pulmonary fibrosis, a progressive, deadly disease resulting in thickening and scarring of the lungs, ...
Lung transplantation is the only curative treatment for IPF, but most patients are ineligible, necessitating focus on slowing disease progression. Nintedanib is recommended for PPF, while pirfenidone ...
Credit: Getty Images. Based on the 2016 International Working Group (IWG) diagnostic criteria for idiopathic pulmonary fibrosis (IPF), outcomes are relatively similar between patients with IPF with ...
Boehringer Ingelheim announced today detailed findings from the Phase III FIBRONEER™-IPF and FIBRONEER™-ILD trials. These studies evaluated nerandomilast, an investigational oral, preferential ...
Nerandomilast, an investigational agent, met the primary endpoint of both phase III trials, FIBRONEER™-IPF and FIBRONEER™-ILD, significantly reducing the decline in forced vital capacity (FVC) [mL] by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback